Human Neurons

Commercial Human Neuron Products

iPSC-Derived Neurons as Research Tools

Human induced pluripotent stem cell technology has transformed neurons from scarce biological specimens into standardized commercial products accessible to research laboratories worldwide. The ability to reprogram adult somatic cells into pluripotent stem cells and then differentiate them into specific neuron subtypes has created an entirely new product category in life science research tools -- one where human neurons are manufactured at industrial scale, quality-controlled for purity and functionality, and shipped as catalog items.

FUJIFILM Cellular Dynamics, a subsidiary of Fujifilm Holdings with over 70,000 employees globally, operates as one of the leading manufacturers of commercial human iPSC-derived neurons. The company portfolio includes iCell GABAergic neurons, dopaminergic neurons, motor neurons, cortical neurons, and microglia -- brain immune cells critical to neuroinflammation research. In September 2024, FUJIFILM Cellular Dynamics launched iCell Sensory Neurons, an off-the-shelf human iPSC-derived cell model targeting pain research and neurotoxicity screening. These sensory neurons demonstrate functional responses to sensory agonists within 21 days of culture, consistent lot-to-lot purity, and are available from both male and female iPSC backgrounds. In April 2025, the company appointed a new chief operating officer to drive business and R&D strategy, signaling continued investment in the commercial neuron product pipeline.

The market for iPSC-derived neural cells serves pharmaceutical companies conducting drug discovery, toxicology testing laboratories assessing neurotoxicity profiles of candidate compounds, and academic researchers modeling neurodegenerative diseases including Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis. Unlike animal-derived neurons or immortalized cell lines, human iPSC-derived neurons provide species-relevant biology that more accurately predicts human clinical outcomes, addressing a critical translational gap in preclinical research.

Disease Modeling and Drug Discovery Applications

Beyond apparently healthy neurons, manufacturers now produce disease-specific neuron models carrying clinically relevant genetic mutations. FUJIFILM Cellular Dynamics offers iPSC-derived dopaminergic neurons with TMEM175 mutations associated with Parkinson disease risk, alongside isogenic control lines for controlled comparison. These disease models enable pharmaceutical researchers to study pathological mechanisms and screen drug candidates against human neurons that recapitulate specific aspects of disease biology -- work that was previously impossible without direct access to patient brain tissue.

Three-dimensional neural culture systems represent the next frontier in commercial neuron products. Brain organoids and neural microtissues assembled from multiple iPSC-derived cell types create more physiologically relevant models of neural circuitry than traditional two-dimensional cultures. These engineered tissues allow researchers to study cell-cell interactions, synaptic connectivity, and network-level activity in controlled laboratory settings, bridging the gap between single-cell assays and whole-brain studies.

Regenerative Neural Cell Therapies

Cell Therapy for Drug-Resistant Epilepsy

While commercial neuron products serve research laboratories, a parallel therapeutic industry is developing human neurons as implantable medicines designed to permanently integrate into patient neural circuits. Neurona Therapeutics, a clinical-stage biotherapeutics company based in South San Francisco, is advancing NRTX-1001 -- the first investigational human cell therapy for drug-resistant epilepsy. NRTX-1001 comprises GABAergic inhibitory interneurons derived from pluripotent stem cells, engineered to restore balanced electrical activity in the brain through a single administration.

Clinical results from Neurona ongoing Phase 1/2 trials have demonstrated compelling efficacy. The low-dose cohort of five patients with drug-resistant mesial temporal lobe epilepsy achieved a 92% median reduction in disabling seizures during the primary evaluation period of seven to twelve months after treatment. The first two patients followed for 24 months continued to report greater than 97% seizure reduction from a single dose. High-dose results showed 78% median reduction in disabling seizures at the interim four-to-six-month assessment. The company has expanded enrollment to include patients without mesial temporal sclerosis and those with bilateral epilepsy, broadening the potential treatment population.

The regulatory trajectory reflects the significance of these results. The FDA granted Regenerative Medicine Advanced Therapy designation to NRTX-1001 in June 2024, and the European Medicines Agency granted Priority Medicines designation in October 2025. In April 2025, Neurona closed an oversubscribed $102 million financing round -- on top of $120 million raised in February 2024 -- to fund the Phase 3 EPIC trial, a randomized, sham-controlled, double-blind study planned to begin dosing in the first half of 2026. Preclinical research published in Neuron in July 2025 demonstrated that 97% of grafted human interneurons developed into on-target somatostatin and parvalbumin subtypes, achieving stable long-term engraftment and functional integration with host circuitry.

Broader Therapeutic Landscape

Neurona is not alone in pursuing neuron-based cell therapies. BlueRock Therapeutics, a Bayer subsidiary, received FDA clearance for an IND application for OpCT-001, an iPSC-derived retinal pigment epithelium therapy developed in collaboration with FUJIFILM Cellular Dynamics and Opsis Therapeutics. While retinal rather than neural in focus, the program validates the broader regulatory pathway for iPSC-derived cell therapies targeting the nervous system. Multiple academic medical centers have performed transplantation procedures as part of clinical trials, with the University of Chicago, Oregon Health and Science University, and the University of Arkansas among sites administering experimental neuron therapies to patients with refractory neurological conditions.

The California Institute for Regenerative Medicine has supported Neurona Phase 1/2 trials through multiple grants, reflecting state-level investment in regenerative medicine infrastructure. The convergence of manufacturing capability from commercial neuron producers with clinical development expertise from therapeutic companies suggests an emerging ecosystem where the same iPSC technology platform serves both research tool and therapeutic applications.

Brain-Inspired Computing and Neuroscience Research

Neuromorphic Chips Modeled on Human Neurons

The third major vertical where human neurons drive commercial activity is semiconductor design. Neuromorphic computing -- the engineering discipline of building computer chips that mimic the structure and function of biological neural networks -- has transitioned from academic curiosity to commercial deployment. Unlike conventional von Neumann architectures that separate memory and processing, neuromorphic chips co-locate computation and storage in artificial neurons and synapses, enabling event-driven processing that mirrors how biological human neurons communicate through electrochemical spikes.

Intel Hala Point system, deployed at Sandia National Laboratories, represents the largest neuromorphic computer built to date. Packaging 1,152 Loihi 2 processors into a chassis the size of a microwave oven, Hala Point supports up to 1.15 billion artificial neurons and 128 billion synapses while consuming a maximum of 2,600 watts -- orders of magnitude more efficient than GPU-based systems performing comparable neural network workloads. Intel Loihi 2 processor itself contains up to one million neurons and 120 million synapses, demonstrating up to 100 times greater energy efficiency on specific AI tasks compared to conventional graphics processors.

IBM NorthPole chip, introduced in 2023, integrates 224 megabytes of on-chip memory to eliminate the data-movement bottleneck entirely, achieving 42,460 frames per joule -- roughly 25 times more efficient than earlier GPU architectures. BrainChip Akida processor has reached mass production, with the AKD1000 running edge AI devices since 2022 and the company launching Akida Cloud in 2025 to provide developer access to neuromorphic computing through cloud infrastructure. Frontgrade Gaisler has integrated BrainChip Akida intellectual property into space-grade processors, demonstrating that neuromorphic AI modeled on human neuron behavior can operate under cosmic radiation and extreme power constraints.

Neuroscience Research Infrastructure

The study of human neurons themselves continues to expand through major research initiatives. The Allen Institute for Brain Science maintains comprehensive atlases of human brain cell types, gene expression patterns, and connectivity maps that serve as reference databases for both academic researchers and commercial product developers. The European Human Brain Project and related initiatives have invested billions in computational neuroscience infrastructure aimed at simulating human neural circuits at increasing scales of biological fidelity.

Multi-electrode array platforms and calcium imaging systems enable researchers to record the activity of thousands of human neurons simultaneously in iPSC-derived cultures, generating datasets that inform both disease research and neuromorphic chip design. The feedback loop between biological neuroscience and computational architecture is tightening: insights from human neuron electrophysiology inspire more biologically faithful chip designs, while neuromorphic simulators enable larger-scale models of neural circuit behavior than biological experiments alone can achieve. Over $200 million in venture capital flowed into neuromorphic startups in 2025 alone, with Intel, IBM, Samsung, and Qualcomm all maintaining active investment positions in this emerging hardware category.

Key Resources

• FUJIFILM Cellular Dynamics -- iPSC-Derived Neural Cell Products
• Neurona Therapeutics -- NRTX-1001 Clinical Development Program
• Intel Labs -- Neuromorphic Computing Research and Loihi Platform
• Allen Institute for Brain Science -- Brain Cell Atlas and Reference Data
• Nature -- Stem Cell Therapies Research Collection